This meeting took place in Baltimore, MD, on September 23-24, 2009, and was presented by the TDM-TOX Division.
The Program
This meeting was designed to review current approaches to personalized medicine in oncology, as well as discuss new and promising developments in this area. In addition to case-based discussions from experts, participants will hear regulatory and payer perspectives on personalized medicine. Continuing education credit will be available for participants.
Meeting presentations will address the following questions: what is the role of therapeutic drug monitoring and pharmacogenomics in management of chemotherapy? How do we overcome current obstacles for implementation of personalized medicine in oncology? Where are some opportunities for utilization of laboratory support in optimization of chemotherapeutic regimens? How do we address the growing need for multidisciplinary support (laboratorian, clinician, pharmacist) to achieve personalized medicine in oncology?
Learning Objectives
The learner will be able to:
- Explain the role of therapeutic drug monitoring and pharmacogenomics in management of chemotherapy
- Evaluate the current obstacles for implementation of personalized medicine in oncology
- Identify and implement opportunities for utilization of laboratory support in optimization of chemotherapeutic regimens
- Justify the need for multidisciplinary support (laboratorian, clinician, pharmacist) to achieve personalized medicine in oncology
Target Audience
Physicians, laboratory directors, clinical pharmacists, pharmacologists, heath care researchers, and residents/fellows with an interest in improving the therapeutic management of oncology patients, sharing perspectives and current practices, exploring new approaches, and determining how to move forward toward personalized medicine in oncology.
Content level: Intermediate to Advanced
System Requirements
The presentations are best viewed with these system requirements:
- Computer: 500MHz with 128MB RAM
- Operating Systems: Windows 98, ME, 2000, XP, Vista or MAC OSX
- Players & Plugins: Adobe Flash Player 8 or higher
- Browsers: View Adobe's web browser requirements
- Audio: Functioning sound card with attached speakers installed
Web Casts
Different Perspectives on Personalized Medicine in Oncology (97 minutes; 0 CE credits)
Two Things to Note (7 minutes)
CE Pippenger, PhD; University of Vermont
Personalized Medicine in Oncology (23 minutes)
Mark Ratain, MD; University of Chicago
Patients, Patents, and Safety Steps in Personalized Medicine (33 minutes)
Kirk Hogan, MD, JD; University of Wisconsin-Madison
Coverage and Payment Issues: Personalized Medicine and Oncology (17 minutes)
Jeffrey Roche, PhD; CMS
Clinical Pharmacology and Personalized Medicine: A Regulatory Science Perspective (17 minutes)
Atiqur Rahman, PhD; FDA
5-Fluorouracil and Capecitabine (50 minutes; 1 CE credit)
Personalized Medicine in Oncology: Management of 5-Fluorouracil (5 minutes)
Session Chair: Barb Zehnbauer, PhD; CDC
Available Tools for Personalized Medicine (19 minutes)
Howard McLeod, PharmD; University of North Carolina
Personalized Medicine in Oncology (26 minutes)
David Flockhart, MD, PhD; Indiana University
Tyrosine Kinase Inhibitors and CML (62 minutes; 1 CE credit)
Personalized Medicine in Oncology Tyrosine Kinase Inhibitors (4 minutes)
Session Chair: Sal Salamone, PhD; Saladax Biomedical, Inc.
Why Should We Care About Imatinib Pharmacokinetics? (13 minutes)
Merrill Egorin, MD; University of Pittsburgh Medical Center
Personalizing Imatinib: Correlating Plasma Levels With Outcome in CML (21 minutes)
Richard Larson, MD; University of Chicago
Heterogeneity in Patient Outcomes for Patients Receiving Imatinib for GISTs (24 minutes)
Robert Maki, MD, PhD; Memorial-Sloan Kettering Cancer Center
Adjuvant Chemotherapy in Breast Cancer (105 minutes; 1.5 CE credits)
Optimization of Therapy for Breast Cancer (3 minutes)
Session Chair: Gwen McMillin, PhD; ARUP Laboratories
Adjuvant Chemotherapy in Breast Cancer (34 minutes)
David Flockhart, MD, PhD; Indiana University
Approaches to Tumor Profiling to Individualize Treatment Decisions in Breast Cancer (34 minutes)
Matthew Ellis, PhD; Washington University
Adjuvant Chemotherapy in Breast Cancer (34 minutes)
Fraser Symmans, MD; M.D. Anderson
EGFR Inhibitors (63 minutes; 1 CE credit)
EGFR Pathways and Cancer (9 minutes)
Session Chair: Pasi Janne, MD; Dana Farber Cancer Institute
EGFR Mutations in Lung Cancer (22 minutes)
William Pao, MD, PhD; Vanderbilt University
Personalized Medicine for the EGFR Inhibitor Cetuximab (32 minutes)
Ed Clark, PhD; Merck
Closing Remarks (12 minutes)
William Clarke, PhD, Conference Chair
Supporters
This program was supported by Abbott Laboratories, ARUP Laboratories, AACC Capital Section, Roche Molecular Systems, Saladax Biomedical and Siemens Healthcare Diagnostics.